Discovery of novel ibrutinib analogues to treat malignant melanoma

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Ibrutinib is a targeted therapy for certain B-cell malignancies.
• The need for novel therapeutic agents against solid tumors, including melanoma, remains high.

Purpose of the Study:

• To synthesize and evaluate novel ibrutinib analogues for antiproliferative activity.
• To investigate the potential of these analogues, particularly YL7, as antimelanoma agents.

Main Methods:

• Synthesis of ibrutinib analogues.
• In vitro evaluation of antiproliferative activity against B lymphoma and solid tumor cell lines.
• Mechanism of action studies including cell cycle, apoptosis, and autophagy.
• In vivo antitumor efficacy assessment in a B16 melanoma model.

Main Results:

• A novel ibrutinib analogue, YL7, demonstrated potent antiproliferative activity across multiple cell lines.
• YL7 exhibited significantly improved efficacy compared to ibrutinib in B16 cells (IC50).
• YL7 inhibited B16 cell proliferation and migration, inducing G1 arrest, apoptosis, and autophagy.
• In vivo studies confirmed YL7's significant inhibition of B16 melanoma growth.

Conclusions:

• Structural modification of ibrutinib can yield potent anticancer agents.
• YL7 shows promising potential as an antimelanoma therapeutic agent.
• Further development of ibrutinib analogues for melanoma treatment is warranted.